Working to Eradicate Gynecologic Cancers

Scientific Plenary IV: Predictors of Outcomes in Gynecologic Cancers: What Can We Learn?

Sunday, March 23, 2014: 11:00 AM-12:45 PM
Ballroom B/C (Tampa Convention Center)
Description:
Moderator:  Adnan R. Munkarah, MD, Henry Ford Health System, Detroit, MI
11:00 AM
Moderator Introductions
A. R. Munkarah
Henry Ford Health System, Detroit, MI
 

 
11:04 AM
Foundation for Women's Cancer Awards
 

 
11:20 AM
A prospective trial evaluating the ability of preoperative CT scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, Fallopian tube, and peritoneal cancer
R. S. Suidan1, P. T. Ramirez2, D. Sarasohn1, J. Teitcher1, S. Mironov1, R. Iyer2, Q. Zhou1, H. Paul3, M. Osaka2 and D. S. Chi3
1Memorial Sloan Kettering Cancer Center, New York, NY, 2The University of Texas MD Anderson Cancer Center, Houston, TX, 3Memorial Sloan-Kettering Cancer Center, New York, NY
 

 
11:31 AM
Predictive model for preoperative determination of microscopic residual disease at the time of primary cytoreduction in patients with advanced-stage epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) 182 analysis
N. S. Horowitz1, A. Miller2, B. J. Rungruang3, T. C. Krivak4, S. D. Richard5, C. A. Hamilton6, N. Rodriguez7, M. A. Bookman8 and G. L. Maxwell9
1Harvard University, Boston, MA, 2Gynecologic Oncology Group, Buffalo, NY, 3Georgia Reagents University, Evans, GA, 4Western Pennsylvania Hospital, Pittsburgh, PA, 5Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA, 6Walter Reed National Military Medical Center, Bethesda, MD, 7Loma Linda University Medical Center, Loma Linda, CA, 8University of Arizona Cancer Center, Tucson, AZ, 9Inova Fairfax Hospital, Falls Church, VA
 

 
11:42 AM
Molecular predictors of residual disease in patients with ovarian cancer
S. L. Tucker1, K. Gharpure1, S. Herbrich1, A. M. Nick1, E. R. King1, R. L. Coleman1, J. Guenthoer2, H. J. Dalton1, K. A. Baggerly1 and A. K. Sood1
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Fred Hutchinson Cancer Research Center, Seattle, WA
 

 
11:53 AM
Lecturette
B. Y. Karlan
Cedars-Sinai Medical Center, Los Angeles, CA
 

 
11:59 AM
Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, Fallopian tube, and peritoneal cancers
J. S. Ferriss1, J. Java2, R. A. Burger3, M. A. Bookman4, G. Fleming5, B. J. Monk6, J. L. Walker7, H. D. Homesley8, J. M. Fowler9, B. E. Greer10 and M. P. Boente11
1Temple University School of Medicine, Philadelphia, PA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Pennsylvania, Philadelphia, PA, 4University of Arizona Cancer Center, Tucson, AZ, 5University of Chicago Medical Center, Chicago, IL, 6University of Arizona Cancer Center, Phoenix, AZ, 7The University of Oklahoma, Oklahoma City, OK, 8East Carolina University, Greensville, NC, 9The Ohio State University, Columbus, OH, 10University of Washington Medical Center, Seattle, WA, 11Minnesota Oncology Hematology PA, US Oncology, Edina, MN
 

 
12:10 PM
Frailty index predicts severe complications in gynecologic oncology patients
S. Uppal, E. M. Hartenbach, L. M. Barroilhet, A. N. Al-Niaimi, R. Spencer, D. M. Kushner, L. W. Rice and S. L. Rose
University of Wisconsin School of Medicine and Public Health, Madison, WI
 

 
12:21 PM
Preoperative quality of life in gynecologic oncology patients: a new predictor of operative risk?
K. M. Doll1, A. C. Snavely2, A. Kalinowski3, D. E. Irwin3, J. T. Bensen3, V. L. Bae-Jump2, J. F. Boggess2, J. T. Soper3, W. R. Brewster3 and P. A. Gehrig2
1University of North Carolina at Chapel Hill, Chapel Hill, NC, Chapel Hill, NC, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, 3University of North Carolina, Chapel Hill, NC
 

 
12:32 PM
Lecturette
V. E. Von Gruenigen
Northeast Ohio Medical University (NEOMED), Rootstown, OH
 
12:37 PM
Questions & Floor Discussion
 
See more of: Scientific Plenary